Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs ...

The gross proceeds of the public offering and private placement to Femasys, before deducting the underwriting and placement agent discounts and commissions and other public offering and private ...

Shares of Femasys Inc. (FEMY) traded 17% lower on Friday morning after the company announced the pricing of an underwritten ...

The Company currently intends to use the net proceeds from the offering to fund further development of the Company's weed management productivity traits in Rice and for working capital and general ...

GDS estimates that the net proceeds from the Primary ADSs Offering will be approximately $123.0 million, after deducting the underwriters’ discount and estimated offering expenses (or approximately ...

J.P. Morgan, BofA Securities, Morgan Stanley and UBS Investment Bank are acting as joint book-running managers, and China Gaaxy International and Guotai Junan International are acting as financial ...

Femasys Inc. (NASDAQ: FEMY) (the "Company” or "Femasys”), a leading biomedical innovator addressing significant unmet needs ...